Tag: Multiple Myeloma
ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
Subcutaneous daratumumab plus pomalidomide and dexamethasone reduces risk of progression, death in relapsed/refractory MM
Triplet Therapy Slows Refractory Multiple Myeloma
Progression-free survival longer with once-weekly selinexor-containing regimen versus standard bortezomib and dexamethasone
COVID-19 Case Fatality Rate 29 Percent in Multiple Myeloma Patients
Increased odds of adverse outcomes seen for Hispanic/Latinos, African-American Blacks versus white patients
Low Vitamin D May Reduce Survival for Some With Multiple Myeloma
Differential effect seen by race, with significantly lower OS for white but not African-American patients
Outcomes Steadily Improve for Multiple Myeloma Treated With ASCT
Patients treated in 2014 or later had superior OS, reduced excess risk for multiple myeloma death
Reirradiation Rarely Required in Focal RT for Multiple Myeloma
For biologically effective dose ≤28 Gy10, small but significant increase seen in reirradiation rates
Frailty Score May Predict Outcomes in Multiple Myeloma
Frailty score based on age, Charlson Comorbidity Index, ECOS PS predicts outcomes in FIRST trial
Lenalidomide Delays Progression in Smoldering Multiple Myeloma
Progression-free survival significantly longer with lenalidomide compared with observation
Use of Novel Therapy, Stem Cell Transplant in MM Varies by Race
African-Americans, Hispanics have longer time from MM diagnosis to novel therapy initiation than whites
Effects on Quality of Life Mixed for Tx of Multiple Myeloma
Reduced pain but worsening of neuropathy seen for IxaThalDex induction tx in relapsed/refractory MM
